VF Corp. Backs FY22 Outlook; Declares Dividend - Quick Facts

While reporting financial results for the second quarter on Friday, VF Corp. (VFC) maintains its adjusted earnings and revenue guidance for the full-year 2022.

For fiscal 2022, the company continues to project adjusted earnings to be approximately $3.20 per share, including an approximate $0.25 contribution from the Supreme brand.

The company also still expects full-year revenues to be approximately $12.0 billion, reflecting growth of approximately 30 percent, including an approximate $600 million contribution from the Supreme brand.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.17 per share on revenues of $11.96 billion for the year. Analysts' estimates typically exclude special items.

Further, VF's Board of Directors declared a quarterly dividend of $0.50 per share, payable on December 20, 2021, to shareholders of record on December 10, 2021. Subject to approval by its Board of Directors, VF intends to continue to pay its regularly scheduled dividend.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT